Description
BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor that inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 = 78 nM). BAY-1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas, and it is undergoing a phase I clinical trial of safety and tolerability for cancer patients